Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Immunoglobulin Light-chain Amyloidosis 3Multiple Myeloma 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER × Focal Adhesion Protein-Tyrosine Kinases × Clear all
NCT05695508 2025-12-24

HD10/DSMMXX

University of Heidelberg Medical Center

Phase 2 Recruiting
160 enrolled
Plasma cell

Multiple Myeloma

NCT07079423 2025-07-23

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06935162 2025-05-25

Teclistamab in Previously Treated AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06699394 2025-04-24

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

Peking University People's Hospital

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡